Latest Property Portfolio News

Centuria Capital Group has announced a fully franked ordinary dividend of AUD 0.052 per security for the six months ending June 30, 2025, payable on August 19, 2025. This steady payout underscores the group's ongoing commitment to delivering shareholder value amid a stable property investment environment.

Region Group reports a $54.4 million uplift in its investment property portfolio valuation as of June 30, 2025, driven by acquisitions and like-for-like gains, while maintaining stable gearing and net tangible assets growth.

Recce Pharmaceuticals has locked in a non-dilutive A$30 million debt facility with Avenue Capital Group, extending its cash runway to support pivotal Phase 3 trials and commercialisation of its synthetic anti-infective R327G.

Adisyn Ltd has successfully completed a key R&D program on low-temperature graphene deposition, earning full approval and final payment of a $520,000 grant from the Israel Innovation Authority. This milestone validates its cutting-edge semiconductor technology aimed at revolutionizing AI and high-performance computing.

Mesoblast reports positive FDA progress on accelerated approval for Revascor in ischemic heart failure and plans a pivotal trial to extend Ryoncil’s label to adults with graft versus host disease, while its US commercial launch outpaces expectations.

Cyclopharm Limited has secured the maximum five-year U.S. patent extension for its flagship Technegas® Kit, extending market exclusivity to 2031 and reinforcing its strategic foothold in pulmonary imaging.

CAQ Holdings Limited has successfully restructured its debt repayment schedule and secured a new RMB 6 million loan facility, positioning itself to support operational growth amid efforts to increase occupancy rates.

Recce Pharmaceuticals has secured a significant patent acceptance in China for its RECCE® anti-infectives, broadening its intellectual property footprint in the world’s second-largest pharmaceutical market.

Argenica Therapeutics has expanded its intellectual property with a new US patent targeting surgically induced strokes, enhancing the commercial potential of its lead drug candidate ARG-007.

Australian Agricultural Company Limited (AACo) reported a 14% rise in operating profit to $58.4 million for FY25, driven by increased sales volumes and disciplined cost control despite challenging market conditions. The company also marked a significant reduction in statutory loss, signaling improved financial resilience.

Anatara Lifesciences has expanded its intellectual property footprint with a 20-year patent granted in Hong Kong for its GaRP gastrointestinal health product, following similar approvals in Europe and Australia. This milestone strengthens its commercial position in the lucrative global market for digestive health solutions.

Mesoblast has been granted a seven-year orphan-drug exclusivity by the FDA for its cell therapy Ryoncil, reinforcing its market position in treating steroid-refractory acute graft versus host disease in children.